These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 30890383)

  • 1. End-user acceptability study of the nanopatch™; a microarray patch (MAP) for child immunization in low and middle-income countries.
    Guillermet E; Alfa DA; Phuong Mai LT; Subedi M; Demolis R; Giersing B; Jaillard P
    Vaccine; 2019 Jul; 37(32):4435-4443. PubMed ID: 30890383
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potential use of microarray patches for vaccine delivery in low- and middle- income countries.
    Peyraud N; Zehrung D; Jarrahian C; Frivold C; Orubu T; Giersing B
    Vaccine; 2019 Jul; 37(32):4427-4434. PubMed ID: 31262587
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Measles vaccination using a microneedle patch.
    Edens C; Collins ML; Ayers J; Rota PA; Prausnitz MR
    Vaccine; 2013 Jul; 31(34):3403-9. PubMed ID: 23044406
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of an Intervention to Use a Measles, Rubella, and Polio Mass Vaccination Campaign to Strengthen Routine Immunization Services in Nepal.
    Wallace AS; Bohara R; Stewart S; Subedi G; Anand A; Burnett E; Giri J; Shrestha J; Gurau S; Dixit S; Rajbhandari R; Schluter WW
    J Infect Dis; 2017 Jul; 216(suppl_1):S280-S286. PubMed ID: 28838201
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety, tolerability, acceptability and immunogenicity of an influenza vaccine delivered to human skin by a novel high-density microprojection array patch (Nanopatch™).
    Fernando GJP; Hickling J; Jayashi Flores CM; Griffin P; Anderson CD; Skinner SR; Davies C; Witham K; Pryor M; Bodle J; Rockman S; Frazer IH; Forster AH
    Vaccine; 2018 Jun; 36(26):3779-3788. PubMed ID: 29779922
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Formulation Development and Improved Stability of a Combination Measles and Rubella Live-Viral Vaccine Dried for Use in the Nanopatch
    Wan Y; Gupta V; Bird C; Pullagurla SR; Fahey P; Forster A; Volkin DB; Joshi SB
    Hum Vaccin Immunother; 2021 Aug; 17(8):2501-2516. PubMed ID: 33957843
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Needle size for vaccination procedures in children and adolescents.
    Beirne PV; Hennessy S; Cadogan SL; Shiely F; Fitzgerald T; MacLeod F
    Cochrane Database Syst Rev; 2015 Jun; (6):CD010720. PubMed ID: 26086647
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Health economics of rotavirus immunization in Vietnam: potentials for favorable cost-effectiveness in developing countries.
    Tu HA; Rozenbaum MH; Coyte PC; Li SC; Woerdenbag HJ; Postma MJ
    Vaccine; 2012 Feb; 30(8):1521-8. PubMed ID: 22119590
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vaccination strategies in developing countries.
    Poore P
    Vaccine; 1988 Oct; 6(5):393-8. PubMed ID: 3057759
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Usability, acceptability, and feasibility of a High-Density Microarray Patch (HD-MAP) applicator as a delivery method for vaccination in clinical settings.
    Davies C; Taba M; Deng L; Karatas C; Bag S; Ross C; Forster A; Booy R; Skinner SR
    Hum Vaccin Immunother; 2022 Nov; 18(4):2018863. PubMed ID: 35100525
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acceptability of microneedle-patch vaccines: A qualitative analysis of the opinions of parents.
    Marshall S; Fleming A; Moore AC; Sahm LJ
    Vaccine; 2017 Sep; 35(37):4896-4904. PubMed ID: 28780122
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The potential effects of introducing microneedle patch vaccines into routine vaccine supply chains.
    Wedlock PT; Mitgang EA; Elsheikh F; Leonard J; Bakal J; Welling J; Crawford J; Assy E; Magadzire BP; Bechtel R; DePasse JV; Siegmund SS; Brown ST; Lee BY
    Vaccine; 2019 Jan; 37(4):645-651. PubMed ID: 30578088
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acceptability of coupling intermittent preventive treatment in infants with the expanded programme on immunization in three francophone countries in Africa.
    de Sousa A; Rabarijaona LP; Ndiaye JL; Sow D; Ndyiae M; Hassan J; Lambo N; Adovohekpe P; Guidetti F; Recht J; Affo A
    Trop Med Int Health; 2012 Mar; 17(3):308-15. PubMed ID: 22128893
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Parents' attitude toward multiple vaccinations at a single visit with alternative delivery methods.
    Kaaijk P; Kleijne DE; Knol MJ; Harmsen IA; Ophorst OJ; Rots NY
    Hum Vaccin Immunother; 2014; 10(8):2483-9. PubMed ID: 25424960
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acceptability and Feasibility of Delivering Pentavalent Vaccines in a Compact, Prefilled, Autodisable Device in Vietnam and Senegal.
    Guillermet E; Dicko HM; Mai le TP; N'Diaye M; Hane F; Ba SO; Gomis K; Tho NT; Lien NT; Than PD; Dinh TV; Jaillard P; Gessner BD; Colombini A
    PLoS One; 2015; 10(7):e0132292. PubMed ID: 26186456
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Measles: summary of worldwide impact.
    Assaad F
    Rev Infect Dis; 1983; 5(3):452-9. PubMed ID: 6878998
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A perspective on controlling vaccine-preventable diseases among children in Liberia.
    Weeks RM
    Infect Control; 1984 Nov; 5(11):538-41. PubMed ID: 6568218
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of vaccine reminder and tracker bracelets on routine childhood immunization coverage and timeliness in urban Pakistan: protocol for a randomized controlled trial.
    Siddiqi DA; Munir M; Shah MT; Khan AJ; Chandir S
    BMC Public Health; 2019 Oct; 19(1):1421. PubMed ID: 31666039
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Microarray patches: scratching the surface of vaccine delivery.
    Choo JJY; McMillan CLD; Young PR; Muller DA
    Expert Rev Vaccines; 2023; 22(1):937-955. PubMed ID: 37846657
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Strengthening national decision-making on immunization by building capacity for economic evaluation: Implementing ProVac in Europe.
    Blau J; Hoestlandt C; D Clark A; Baxter L; Felix Garcia AG; Mounaud B; Mosina L
    Vaccine; 2015 May; 33 Suppl 1():A34-9. PubMed ID: 25919171
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.